GENELUX CORPORATION Financing Cash Flow
GENELUX CORPORATION (GNLX) reported Financing Cash Flow of $18.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- GENELUX CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $387.00K, a 644.23% increase year-over-year.
- GENELUX CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $18.54M, a 93.77% increase year-over-year.
- GENELUX CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $276.00K, a 203.30% increase year-over-year.
- GENELUX CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- GENELUX CORPORATION net cash provided by (used in) financing activities for fiscal 2025 was $9.89M, a 65.29% decline from fiscal 2024.
- GENELUX CORPORATION net cash provided by (used in) financing activities for fiscal 2024 was $28.51M, a 35.24% decline from fiscal 2023.
- GENELUX CORPORATION net cash provided by (used in) financing activities for fiscal 2023 was $44.02M.
- GENELUX CORPORATION net cash provided by (used in) financing activities for fiscal 2022 was -$478.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $18.93M 10-Q · filed 2026-08-13 | $19.20M derived: sum of 3 quarters · filed 2026-08-13 | $19.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $18.54M 10-Q · filed 2026-05-07 | $18.81M derived: sum of 2 quarters · filed 2026-05-07 | $18.81M derived: sum of 3 quarters · filed 2026-05-07 | $18.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $276.00K derived: sum of 2 quarters · filed 2026-03-19 | $328.00K derived: sum of 3 quarters · filed 2026-08-13 | $9.89M 10-K · filed 2026-03-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $52.00K derived: sum of 2 quarters · filed 2026-08-13 | $9.62M 10-Q · filed 2025-11-05 | $9.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $9.62M 10-Q · filed 2026-08-13 | $9.71M derived: sum of 3 quarters · filed 2026-08-13 | $9.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $9.57M 10-Q · filed 2026-05-07 | $9.66M derived: sum of 2 quarters · filed 2026-05-07 | $9.66M derived: sum of 3 quarters · filed 2026-05-07 | $37.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $91.00K derived: sum of 2 quarters · filed 2026-03-19 | $27.82M derived: sum of 3 quarters · filed 2026-03-19 | $28.51M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $27.73M derived: sum of 2 quarters · filed 2025-11-05 | $28.41M 10-Q · filed 2025-11-05 | $28.82M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $27.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $28.41M 10-Q · filed 2025-08-07 | $28.82M derived: sum of 3 quarters · filed 2025-08-07 | $35.18M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $688.00K 10-Q · filed 2025-05-06 | $1.09M derived: sum of 2 quarters · filed 2025-05-06 | $7.45M derived: sum of 3 quarters · filed 2025-05-06 | $30.07M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $6.76M derived: sum of 2 quarters · filed 2025-03-28 | $29.38M derived: sum of 3 quarters · filed 2025-03-28 | $44.02M 10-K · filed 2025-03-28 |
| 2023-09-30 | $6.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $28.98M derived: sum of 2 quarters · filed 2024-11-14 | $43.62M 10-Q · filed 2024-11-14 | $44.16M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $22.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $37.26M 10-Q · filed 2024-08-14 | $37.80M derived: sum of 3 quarters · filed 2024-08-14 | $37.47M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $14.64M 10-Q · filed 2024-05-09 | $15.19M derived: sum of 2 quarters · filed 2024-05-09 | $14.86M derived: sum of 3 quarters · filed 2024-05-09 | $14.29M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $545.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $216.00K derived: sum of 2 quarters · filed 2024-03-29 | -$348.00K derived: sum of 3 quarters · filed 2024-03-29 | -$478.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | -$329.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$893.00K derived: sum of 2 quarters · filed 2023-11-14 | -$1.02M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$564.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$694.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$130.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |